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In 178 patients, a randomized prospective comparison between the 60° spherical disc Bjork-Shiley (BS) and
the St Jude Medical (SJM) heart valve prostheses was performed. Four-week perioperative mortality was
zero in the BS (n = 84) and 4-3% in the SJM group (n = 94). During a mean ( ± SD) follow-up of 52 ± 20
months or 778patient-years, late cardiac mortality per year was 2-4%> in the BS and 2-2% in the SJM group.
The yearly thromboembolic rates were 1-4% in the BS and 20% in the SJM group. There was no mechanical
valve failure or haemolytic anaemia. Paravalvular leaks and major bleeding complications occurred at low
rates in both groups (1-1% and2-2% per year in BS; 0-7% and 1-7% per year in SJM). Functional results
were similarly good with 96% of patients with BS valves and 95% of patients with SJM prostheses being in
NYHA classes landII, respectively.
We conclude that heart valve replacement with mechanical prostheses can be performed with equally good
results using either the Bjork-Shiley spherical disc valve or the St Jude Medical bileqflet prosthesis.
Introduction made in 178 patients. These included 112 men and
Manufacturers of mechanical heart valve prostheses M w o m e n a « e d >-76 y e a r s ' I n 8 4 P a t i e n t s 9 5 B S
claim advantages such as improved haemodynamic P™stheses were implanted, and 94 patients received
performance, low thrombogenicity and a lower 1 0 9 S J M P™stheses. Detailed patient character-
mechanical failure rate because of specific design i s t i c s a r e &ven i n T a b l e ' • The t w 0 P a t i e n t 8 r o uP s
characteristics!'-2-"-12'. Whether this is of clinical w e r e comparable as to age and sex distribution,
importance is largely unknown. Therefore a series l o c a t i o n a n d n u m b e r of implants as well as cardiac
of 178 patients were followed closely after valve diagnosis. All candidates for a mechanical valve
replacement for an average 52 ±20 m o n t h s - a substitute were randomized and all accepted the
total of 778 patient-years; in this series, either the v a l v e suggested. In order to give comparable
Bjork-Shiley (BS) 60° spherical disc valve or the St « r o uP s ' randomization was performed according
Jude Medical (SJM) bileaflet valve were selected for t o underlying heart disease, pre-operative cardiac
implantation in a randomized fashion. r h y t h m a n d concom.tant surgery.
Methods
PATIENTS OPERATIVE TECHNIQUES
From January 1981 until October 1983, a ran- All patients were operated on by the same surgi-
domized allocation of BS or SJM prostheses was cal t e a m w h o h a d previous extensive experience
with both types of prostheses. All were operated on
™
 PubliCiti0n
 °"
 4 My l989> and in reviied form 2
 by stemotomy, using cardio-pulmonary bypass and
cold potassium cardioplegia or coronary perfusion
S^^^^'S^u1^^ f o r "yocaidial protection. The prostheses were
Basel/Switzerland. implanted with the interrupted suture technique.
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Table 1
fashion
Characteristics of 178 patients receiving a BS or SJM prosthesis in a randomized
BS SJM
N total
mean age ± SD, years
age range, years
male sex (%)
aortic valve replacement (%)
mitral valve replacement (%)
double valve replacement (%)
predominant aortic stenosis (%)
predominant aortic regurgitation (%)
predominant mitral stenosis (%)
predominant mitral regurgitation (%)
balanced lesions (%)
rheumatic heart disease (%)
myxold degeneration (%)
infectious endocarditis (%)
various etiologies (%)
concomitant coronary artery disease (a) (%)
papillary muscle dysfunction
preoperative NYHA grades III + IV
patients with ejection fraction < 50 (b) (%)
perioperative atrial fibrillation (%)
mean aortic size (mm)
mean mitral size (mm)
mean observation time (months)
range
P value
84
58-1 ±11-5
19-76
59-5
57 1
29-8
131
36-9
20-2
16-7
131
13 1
84-5
9-5
2-4
3-6
15-5
2-4
59-5
131
22-6
24-3
27-9
52-3± 19 17
(25-83 9)
94
55-4±140
1-76
660
500
340
160
30-9
191
13-8
10-2
26
77-7
12 8
3-2
6 3
11-7
21
38-3
7-4
24-5
23-5
27-6
51-7±I8 -9
(25-82-5)
—
>0-l
—
>0-2
> 0 2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
>0-2
<0005
>0-2
>0-2
(a) defined as a > 75% luminal narrowing of one or more major coronary vessels, (b) measured
in all patients.
FOLLOW-UP
The patients were followed up at a specialized
outpatient clinic, where at each visit a complete his-
tory, physical examination, chest X-ray, 12-lead
resting ECG and laboratory parameters for haemo-
lysis were taken. Echocardiography and Doppler
sonography were not routinely used in these
patients. A thromboembolic event was denned as
any new transient or permanent neurological deficit
or other peripheral arterial embolic episode1141. The
patients were seen 3 months postoperatively and
yearly thereafter during a mean (± SD) of 52 ± 20
months (BS) and 52 ±19 months (SJM). The
follow-up duration ranged from 25 to 84 months.
The number of patient-years in aortic valve replace-
ment was 209 (BS) and 203 (SJM); in mitral valve
replacement, 109 (BS) and 138 (SJM). All patients
were on oral anticoagulants with coumarin deriva-
tives, with INR values aimed at 2-8-4-3. A total of
five patients were lost to follow-up (four in the
Bjork-Shiley group and one in the St Jude Medical
group).
STATISTICAL ANALYSIS
Randomization was performed within subgroups
of patients according to concomitant surgery,
underlying disease, valve position and heart
rhythm. For comparison between the groups, the
chi-square test was used. Actuarial survival was
calculated accordingto Kaplan and Meier1'01.
Results
OPERATIVE AND EARLY MORTALITY
In the BS group, there was no death during
operation or within the first 4 postoperative weeks.
In the SJM group there were four deaths during
the perioperative period (4-3%). One patient died
during operation of an intractable aortic tear.
During the 4-week postoperative course one patient
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Figure I Actuarial survival curves in two groups of patients
randomly receiving Bjork-Shiley (BS) or St Jude Medical
(SJM) heart valve prostheses. The small numbers below the
time axis indicate patients at risk. The sections indicated in
the curves show 95% confidence limits. The curves are age-
and sex-adjusted for an expected survivorship in Switzerland
(1982).
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Figure 2 Actuarial incidence rates of thromboembolic com-
plications in two groups of patients randomly receiving
Bjork-Shiley (BS) and St Jude Medical (SJM) prostheses. The
small numbers below the time axis indicate patients at risk.
The sections indicated in the curves show 95% confidence
limits.
died from intractable sepsis, one patient from pump
failure and one patient from renal failure.
LATE MORTALITY
Survival curves were virtually identical (/*>0-2)
in patients receiving BS and SJM prostheses (Fig.
1). During follow-up there were nine cardiac deaths
in the BS group, resulting in a yearly cardiac mor-
tality of 2-4%. There were five witnessed sudden
deaths, two cases of pump failure and two patients
with fatal haemorrhage. In addition there were
three non-cardiac deaths (one suicide, carcinoma,
pulmonary embolism in metastatic cancer). In the
SJ M group there were nine cardiac deaths, resulting
in a yearly cardiac mortality of 2-2%. There were
three witnessed sudden cardiac deaths, two patients
with pump failure, one patient with endocarditis,
two patients with fatal haemorrhages and one
further patient with aortic rupture.
MECHANICAL VALVE FAILURE AND HAEMOLYSIS
There were no cases of mechanical valve dysfunc-
tion or thrombotic obstruction in either the BS or
the SJM group. Anaemia with a haemoglobin
value below 12g% and a reticulocyte count of
> 10%o was observed in none of the patients. An
LDH level exceeding 500 U 1~' was seen in one
patient with a BS-valve with a para valvular leak. In
the two patients with SJM valves and paravalvular
leaks, the LDH levels were normal.
THROMBOEMBOLISM
Thromboembolic event rates were 1 -4% per year
and 20% per year in the BS and SJM group, respect-
ively. The actuarial incidence of thromboembolic
complications was identical (P>0-2) in the two
groups (Fig. 2) Thromboembolic events separated
for valve position and type of prosthesis are shown
in Figs 3 and 4. The differences between the two
valve substitutes were not statistically significant,
although the relatively high incidence of thrombo-
embolic complications in BS mitral prostheses and
SJM aortic valves is worth mentioning, contrasting
with the lack of thromboemboli in patients after BS
aortic valve replacement. The detailed thrombo-
embolic rates according to prosthesis type and lo-
cation are shown in Table 2. Thromboembolism
occurred with adequate anticoagulation (i.e. INR
levels between 2-8-4-3) in four of five cases in the BS
group, and in three of eight cases in the SJM group.
There were no permanent sequelae in two of five BS
and seven of eight SJM patients. There were no fatal
thromboembolic events.
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Figure 3 Actuarial incidence rates of thromboembolic compli-
cations in BS prostheses, separated into aortic and mitral valves. The
small numbers below the time axis indicate patients at risk. The
sections indicated in the curves show 95% confidence limits.
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Figure 4 Actuarial incidence rates of thromboembolic compli-
cations in SJM protheses separated into aortic and mitral valves. The
small numbers below the time axis indicate patients at risk. The
sections indicated in the curves show 95% confidence limits.
PARA VALVULAR LEAKS
Angiographically documented paravalvular
leaks necessitating reoperation occurred in one
patient with a BS aortic valve and in two patients
with SJM mitral valves. In addition, there were
paravalvular leaks without haemodynamic signifi-
cance in three patients with BS (two aortic and one
mitral) prostheses and one patient with an SJM
aortic valve, all documented by Doppler echo-
cardiography. This gives a paravalvular leak
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Table 2 Thromboembolie rate per 100 patient years of 95
patients after aortic valve replacement (48 BS. 47 SJM). 57
patients after mitral valve replacement (25 BS, 32 SJM) and
26 patients after double valve replacement (11 BS. 15 SJM)
BS SJM
Aortic position
Mitral position
Double implant
All
0
4-6
1-9
1-4
30
2-2
0
20
n.s.
n.s.
n.s.
n.s. = not significant.
incidence of 1-1 % and 0-7% for BS valves and SJM
prostheses, respectively.
COMPLICATIONS SECONDARY TO ANTICOAGULATION
Lethal bleeding occurred in two patients with a
BS valve (both cerebral haemorrhages) and in
two patients with a SJM valve (one cerebral, one
gastrointestinal). In none of these patients was
the prothrombin time known at the time of death.
Major non-fatal bleeding occurred in six patients
with BS valves (four gastrointestinal, one intra-
cranial, one pericardial) and in five patients with
SJM valves (two gastrointestinal, two intracranial,
one ovarian). Minor bleeding occurred in one
patient in each group (one epistaxis, one subcu-
taneous). The annual incidence of major bleeding
complications was therefore 2-2% and 1-7% for BS
and SJM valves, respectively.
Cumulative yearly event-free rates defined as free
from death, thromboembolism, reoperation, valve
dysfunction, endocarditis and major bleeding are
shown in Fig. 5. No significant difference (P>0-2)
is seen between the two groups with BS and SJM
prostheses. The detailed event-free rates according
to prosthesis type and location did not show any
significant difference and are given in Figs 6 and 7.
FUNCTIONAL RESULTS
Of the patients with BS prostheses 68% were in
class I and 28% in class II of the NYHA postopera-
tively. Corresponding figures for the SJM group
were 65% in class I and 30% in class II (Fig. 8).
Therefore, postoperatively 96% and 95% of
patients in the BS and SJM groups were in NYHA
classes I or II, respectively. The percentage of
patients in sinus rhythm pre- and postoperatively
was 73 and 79 in BS vs 75 and 88 in SJM patients.
76 %
74%
Years after operation
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Figure 5 Cumulative yearly event-free rates (event = death,
reoperation, thromboembolism, major bleeding, valve dys-
function, infectious endocarditis). The small numbers below
the time axis indicate patients at risk. The sections indicated
in the curves show the 95% confidence limits.
Normalization of a preoperatively abnormal car-
diothoracic ratio occurred in 37% of BS and 41 % of
SJM patients (Table 3).
Discussion
Two prostheses of quite different design were
compared in a randomized prospective study in
patients eligible to receive a mechanical valve
substitute. Despite differences in valve area and
haemodynamic flow patterns1"1, clinical results with
the two prostheses were nearly identical in our
population.
Operative and early (4 weeks) mortality in our
total population was 2-2%, which is lower than
figures from other centres15'7'13'. This is probably due
to the fact that only few patients with ischaemic
heart disease, with ejection fraction below 50% and
in NYHA class IV were included. All these factors
are known to influence perioperative mortality and
postoperative prognosis'5'. There was no significant
difference in mortality between the two groups of
patients. Similarly, late annual mortality in both
groups was low, being 2-4% for patients with BS,
and 2-2% for patients with SJM prostheses. This
compares favourably with data reported from
Duncan et al.m, who found a yearly mortality rate
of 2-5% in 253 patients after aortic or mitral valve
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Figure 6 Cumulative yearly event-free rates (event = death, reoper-
ation, thromboembolism, major bleeding, valve dysfunction,
infectious endocarditis) for BS prostheses, separated into aortic and
mitral valves. The small numbers below the time axis indicate
patients at risk. The sections indicated in the curves show the 95%
confidence limits.
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Figure 7 Cumulative yearly event-free rates (event = death, reoper-
ation, thromboembolism, major bleeding, valve dysfunction,
infectious endocarditis) for SJM prostheses, separated into aortic
and mitral valves. The small numbers below the time axis indicate
patients at risk. The sections indicated in the curves show 95%
confidence limits.
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Figure 8 Functional classification according to the New York Heart Association
(NYHA) before and after operation in two groups of patients with Bjork-Shiley (BS)
and St Jude Medical (SJM) heart valve prostheses. AVR = aortic valve replacement;
MVR = mitral valve replacement; DVR = double valve replacement. D=classl; • =
class II: D =class III; • =class IV.
Table 3 Pre- and postoperative rhythm- and chest X-ray
findings in patients with BS and SJM prostheses
BS SJM
% patients in sinus
rhythm pre- and post-
operatively 73/79 75/88
% patients with a CTR
<0-5pre-andpost-
operatively 17/54 30/71
replacement with the SJM prosthesis and with find-
ings from Sethia and coworkers'131, who reported a
yearly mortality of 2-9% in 729 patients with the
standard BS valve.
Thromboembolic events occurred with an equally
low incidence in the BS (1-4% per year) and SJM
group (20% per year). These findings are in con-
trast with those reported by Horstkotte et al.p\ who
found a thromboembolic rate of 12-5% in the first
year after mitral valve replacement with the BS
prosthesis, but no thromboemboli with the SJM
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mitral valve. However, in their study group allo-
cation was not performed in a randomized fashion,
so the BS group included more patients with mitral
regurgitation, accompanying valve disease, long
history of symptoms, prior valve surgery and atrial
fibrillation. In a later publication, the same authors
reported a lower thromboembolic rate of 2-82 and
1 -93 per 100 patient-years after BS mitral or aortic
valve replacement, respectively, which was still
higher than their figures found after valve replace-
ment with the SJM prosthesis (0-93% mitral, 0-73%
aortic)1'1. Other authors found, as we did, a similar
incidence of thromboembolism in different mech-
anical valves. In a prospective study, Chesebro et
a/.(4! found an incidence of thromboembolism,
ranging from 1 -2 to 1 -8% per year in patients after
valve replacement with the Starr-Edwards (SE), BS
or SJM prostheses. Chaux et alP] described com-
parable rates of thromboembolism with the BS and
the SE prostheses. In another prospective study,
Douglas et a/.'6' observed a thromboembolic rate of
2-8% per patient-year after aortic valve replace-
ment with the SJM prosthesis, which was not
significantly higher than the 1-5% recorded after
implantation of an aortic porcine heterograft.
When our data were treated with the actuarial
method, 93% of patients with BS and 90% of
patients with SJM prostheses were free of thrombo-
embolic events after 5 years. These figures are
comparable to those of Sethia et a/.'13', who
observed a freedom from thromboembolic events in
94% of their patients with BS prostheses after 4
years. Seven of the 13 thromboembolic events in our
study occurred with adequate anticoagulation (four
of five in the BS group and three of eight in the
SJM group). Analysis of thromboembolic events
according to valve location showed no significant
differences between valve types.
A paravalvular leak occurred in seven of our
patients (four BS and three SJM), necessitating
reoperation in three patients (one BS, two SJM).
This corresponds to an annual reoperation rate of
0-4% in the BS group and 0-8% in the SJM group.
These figures again compare well to those reported
by Sethia et alP\ who found a reoperation rate
of 0-8% per year in his patients receiving BS
prostheses.
The functional results were equally good in both
groups. In the BS group, 60% of patients were pre-
operatively in NYH A classes III or IV, but only 4%
were in NYHA class III after valve replacement. In
the SJM group, 39% of all patients were pre-
operatively in NYHA classes III and IV and only
5% were in NYHA class III after surgery. Similar
functional results were reported by Duncan'71
and Horstkotte181. This equally good functional
result was achieved in both groups despite the
fact that patients receiving a BS prosthesis were
preoperatively more symptomatic.
Thus, cumulative complication rates were simi-
larly low and equally excellent functional results
were achieved despite a difference of the pre-
operative functional state of patients in the two
groups. As regards all other relevant variables, the
two groups were comparable. This was achieved by
using several randomization subgroups according
to underlying disease, preoperative heart rhythm
and concomitant surgery. This is also the reason for
the different number of patients in the two groups.
The rather small number of patients in the dif-
ferent subgroups in this study makes a statistical
analysis of our data difficult. However, due to the
low event rate expected one would have to include
over 3000 patients in each group to detect a statisti-
cally significant difference between two groups with
a power of 0-8 and a P value of 005. Therefore it
did not seem reasonable to plan a much larger
study, because even a multicentre approach would
not have significantly altered the weak statistical
power1151.
From the results of this randomized prospective
study, there seems to be no clinical relevance for
the manufacturers' claim of a lesser degree of
transvalvular regurgitation in the BS nor a lower
thrombogenicity in SJM prostheses.
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